Zura Bio Ltd
ZURA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855644
No open-market purchases or sales by Zura Bio Ltd insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $428.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 28, 2026, 12:35 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 25, 2025 | Mar 28, 2024 | – |
| Operating expenses | $75.2M | $55.2M | $62.6M | – |
| Research and development | $42.1M | $24.4M | $44.0M | – |
| Selling, general and administrative | $33.2M | $30.8M | $18.6M | $2.29M |
| Operating income | -$75.2M | -$55.2M | -$62.6M | -$2.68M |
| Income tax | – | $0 | $0 | – |
| Net income | -$68.7M | -$52.4M | -$60.4M | $3.55M |
| EPS, basic | $-1.06 | $-0.60 | $-2.09 | – |
| EPS, diluted | $-1.06 | $-0.60 | $-2.09 | – |
| Weighted shares, basic | 94.2M | 75.1M | 33.1M | – |
| Weighted shares, diluted | 94.2M | 75.1M | 33.1M | – |
| Margins and growth | ||||
| Net income growth, year over year | – | – | −1,800.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024! | FY2023! | FY2022! |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 25, 2025 | Mar 28, 2024 | – |
| Cash and equivalents | $109.4M | $176.5M | $99.8M | $13.8K |
| Total current assets | $112.3M | $178.7M | $100.8M | $33.5K |
| Property, plant and equipment | $126.0K | $91.0K | – | – |
| Total assets | $113.9M | $179.5M | $100.8M | $141.5M |
| Accounts payable | $1.28M | $733.0K | $2.75M | $282.1K |
| Total current liabilities | $12.4M | $19.5M | $20.3M | $1.83M |
| Total liabilities | $12.4M | $19.5M | $21.3M | $7.76M |
| Shareholders' equity | $101.5M | $148.4M | $60.9M | -$7.63M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 25, 2025 | Mar 28, 2024 | – |
| Operating cash flow | -$64.8M | -$28.1M | -$15.1M | -$1.07M |
| Capital expenditures | $113.0K | $75.0K | – | – |
| Free cash flow | -$64.9M | -$28.2M | – | – |
| Depreciation and amortization | $49.0K | $9.00K | – | – |
| Stock-based compensation | $12.3M | $16.8M | $7.47M | – |
| Investing cash flow | -$113.0K | -$5.08M | -$8.00M | – |
| Financing cash flow | -$2.16M | $109.8M | $121.3M | $355.6K |
| Net change in cash | – | – | – | -$715.4K |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.